Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10642)	2/26/2004 1:00:17 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 52153

Creative Biomolecules... I remember those days: Stryker bought some of the company and the R&D part became Curis. I did some work at the old CBMI in Hopkinton,MA and New Lebanon, NH. Have always been skeptical of their ability to deliver. Nothing came out of the investment that Biogen made (that I know of), nothing has come out of Elan's investment (that I know of), and the compound CBMI and BGEN collaborated on for treatment of renal failure had soluability issues. What has CBMI succeeded with?

To: scaram(o)uche who wrote (10642)	3/1/2004 3:09:59 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 52153

Rick: I've been paying a lot of attention to CRIS. It's not actually fair to depict them as CBMI in a new wrapper: the CBMI management, which was prone to overspending and underproduction, was dumped when Ontogeny acquired CBMI and Reprogenesis. Of course, Ontogeny's management was bizarre as well, for different reasons that are probably irrelevant now. But the BOD brought in Passeri last year and he seems to have focused them pretty well. But that's not what I am interested in. Besides the euphonious quality of the sonic and desert hedgehog monikers, the Curis small molecule hedgehog agonists are thus far, to my knowledge, the only small molecules that appear to increase neurogenesis. If one presumes--as I do--that such neurogenesis might be useful in CNS regeneration, this is exciting. They say they'll be in the clinic the end of this year, and that is reason enough for me to watch. The fact that Wyeth partnered that program, Genentech partnered the antagonists, and Ortho is developing BMP-7 for renal disease (and eventually stroke, perhaps) are all to the good. But it's that small molecule neurogenesis enhancement that is Curis' raison d'etre. OK. Now you can all go back to thinking about how much money you would have made on Sepracor. Personally, I'm trying to not dwell on it too much. But could someone explain the point of 'resubmitting the NDA?' I think that the delay (which I am projecting will be until 4Q, simply because the FDA has been so laggard on this), reduces what was once an 18 month time lead on indiplon to...9-12 months or so. That's not much of a head start on the Pfizer blitzkrieg.Objects in their rear view mirror 'truly will be closer than they appear'. Harry NeuroInvestment